Last Updated : April 30, 2025
Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Reimburse with clinical criteria and/or conditions | Complete | ||
Voranigo | vorasidenib | Astrocytoma or oligodendroglioma; IDH1 or IDH2 mutation | Pending | |||
Vosevi | sofosbuvir velpatasvir voxilaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete | ||
Voydeya | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Reimburse with clinical criteria and/or conditions | Complete | ||
VPRIV | Velaglucerase alfa | Gaucher Disease | List with clinical criteria and/or conditions | Complete | ||
Vraylar | cariprazine | Schizophrenia | Reimburse with clinical criteria and/or conditions | Complete | ||
Vraylar | cariprazine | Bipolar Disorder | Do not reimburse | Complete | ||
Vraylar | cariprazine | Schizophrenia | Do not reimburse | Complete | ||
Vyalev | foslevodopa foscarbidopa | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyloy | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Reimburse with clinical criteria and/or conditions | Active | ||
Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyndaqel | tafamidis | Transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyvgart | efgartigimod alfa | Chronic inflammatory demyelinating polyneuropathy | Pending | |||
Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Wainua | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Wegovy | semaglutide | Weight management | Active |